William Blair research analyst Matt Phipps was quoted in this CNBC outlook story covering how healthcare stocks will perform in 2023.
“Several companies that had provided strong clinical data were able to raise funds [in 2022],” Phipps said.
Equity Research
William Blair research analyst Matt Phipps was quoted in this CNBC outlook story covering how healthcare stocks will perform in 2023.
“Several companies that had provided strong clinical data were able to raise funds [in 2022],” Phipps said.
Stay up-to-date with the latest William Blair news and insights
William Blair initiated research coverage of Inari Medical, Inc. (NARI $54.73), a medical device company that develops interventional products for patients suffering from venous diseases.
Read moreThis charitable vehicle provides a simplified approach that allows you to maximize your charitable donations and tax benefits—an approach that can transform the way you give.
Read moreWilliam Blair acted as the exclusive financial advisor to Clio in connection with its $900 million Series F investment round led by New Enterprise Associates, at a $3.0 billion valuation.
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures